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ReviewBeginning to Understand the End
of the Chromosome
zymatic activity was the subject of Greider and Black-
burn (1985). The activity added TTGGGG repeats, one
nucleotide at a time, to the ends of GT-rich primers
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University of Colorado that represented either the Tetrahymena or the yeast
telomeric sequence. This paper marked the first appear-Boulder, Colorado 80309
ance in the literature of the six nucleotide “ladder” of
extension products that would appear in a hundred sub-
sequent papers—a hallmark of telomerase activity notIn their 1985 Cell paper, Greider and Blackburn an-
nounced the discovery of an enzyme that extended just in Tetrahymena, but in human extracts as well. The
authors made the reasonable proposal that the activitythe DNA at chromosome telomeres in the ciliate, Tet-
rahymena. Since then, there has been an explosion of might be related to known terminal transferases, such
as the enzyme that adds CCA to the 3 ends of transferknowledge about both the RNA and protein subunits
of this unusual ribonucleoprotein enzyme in organisms RNAs. The real nature of the enzyme turned out to be
much more novel.ranging from the ciliates to yeast to humans. The regu-
lation of telomerase is now understood to take place
both at the level of synthesis of the enzyme and via Telomerase Contains an Essential RNA
the state of its substrate, the telomere itself. The roles In the following years, Greider and Blackburn found that
of telomerase in both cellular immortality and cancer the enzyme (now called telomerase) was even much
are vibrant areas of current research. more interesting than one might have thought. It con-
tained an essential RNA component, a portion of which
served as a template to specify the sequence that was
It is unusual for an enzyme to be a topic of widespread added to the chromosome end (Greider and Blackburn,
conversation. While millions may marvel at the lower 1989; Figure 1). The rules were those of Watson-Crick
cholesterol levels they’ve achieved by taking a statin, base-pairing: C’s and A’s in the RNA template specified
few of them know that the drug inhibits their HMG-CoA G’s and T’s, respectively, in the sequence that was laid
reductase enzyme. Telomerase, on the other hand, is down at chromosome ends. Indeed, the formal proof
connected to notions of our mortality and longevity and of this model was provided in an elegant paper from
has been popularized by articles and books including Blackburn’s lab, in which site-specific mutagenesis of
“Merchants of Immortality” (Hall, 2003). The purpose of nucleotides in the RNA template led to the deposition of
this review is to celebrate the Greider and Blackburn complementary nucleotides in Tetrahymena telomeres
paper that started it all and then to highlight some of (Yu et al., 1990).
the major advances that followed. My review will be Subsequently, Greider’s group at Cold Spring Harbor
highly selective, covering only about 1% of the hundreds Laboratory collaborated with scientists at Geron Corpo-
of scientific papers written each year that deal with telo- ration to identify and sequence the telomerase RNAs
merase, and I refer the reader to other recent reviews from mouse and human—the ribonucleoprotein nature
for a more comprehensive treatment (e.g., Blackburn, of telomerase was general (Feng et al., 1995). She also
2001; Collins and Mitchell, 2002). worked with Ron DePinho to construct a mouse knock-
out for the RNA. The homozygous null mice were re-
Telomere Terminal Transferase markable in that they were viable for six generations
Carol Greider, a graduate student in Liz Blackburn’s (Blasco et al., 1997). The explanation is that the mice
group at the University of California, Berkeley, had cho- start with long telomeres (1060 kb); the failure to repli-
sen an ambitious PhD thesis project: identify the molec- cate those telomeres leads to gradual loss of terminal
ular entity responsible for replicating chromosome ends. DNA sequences, but it takes many cell divisions before
There was a basis for thinking that such an activity would the shortest telomeres reach a critical length. Embryonic
exist: when linear DNA molecules from ciliated protozoa fibroblasts cultured from the fourth generation of these
were propagated in yeast, their ends were extended mice onward showed aneuploidy and chromosome
not by the ciliate telomeric DNA sequence (repeats of end-to-end fusions, indicative of failure to cap chromo-
TTGGGG in Tetrahymena or T4G4 in hypotrichous cili- some ends.
ates), but instead by the more heterogeneous G1-3T yeast
telomeric sequence (Szostak and Blackburn, 1982; Pluta Finally, the Protein: Telomerase
et al., 1984; Shampay et al., 1984). One reasonable inter- Reverse Transcriptase
pretation was that the ciliate telomeres served as Greider and Blackburn (1985) provided indirect evidence
“seeds” for addition of a DNA sequence that was speci- that telomerase contained at least one essential protein
fied by a nucleotide addition activity intrinsic to yeast. component, which presumably provided the catalytic
Greider’s project was to purify the corresponding Tetra- center for nucleotide addition. The protein proved elu-
hymena enzyme. sive, however, and it took ten years for two different
The identification and characterization of this new en- approaches to converge on its identification. Joachim
Lingner purified active telomerase from Euplotes, a cili-
ated protozoan with an extraordinary number of telo-*Correspondence: thomas.cech@colorado.edu
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Figure 1. Telomerase in Action
The RNA subunit (purple) has the template sequence of Tetrahy-
mena telomerase. Proteins include the catalytic subunit, TERT (yel-
low), and additional less-conserved proteins (orange). Reprinted
with permission from Cech (1994). Illustration by K. Sutliff. Copyright
1994 AAAS.
meres per macronucleus (ca. 108) and a correspondingly
high dose of telomerase (Lingner and Cech, 1996). It
contained the telomerase RNA and two proteins, p123
and p43. At the same time, a genetic screen in yeast
in Vicki Lundblad’s lab identified three genes whose
deletion resulted in an EST (Ever Shorter Telomeres)
phenotype (Lendvay et al., 1996). It turned out that the
best sequence match to Euplotes p123 was Lund-
blad’s Est2p.
Better yet, both p123 and Est2p contained the amino
acid sequence hallmarks of reverse transcriptases. It
had long been thought that telomerase resembled a Figure 2. Telomerase Reaction Cycle
reverse transcriptase (RT), in that it synthesized DNA The RNA subunit is held into the complex by interactions with the
N-terminal domain of TERT. This leaves the template (CA-containingusing an RNA template. It now appeared that it was
sequence) free to move through the RT domain so that a single activedirectly related to other RTs in terms of its protein struc-
site (triangle) can catalyze nucleotide addition at multiple positions.ture and evolution. The critical evidence came from a
collaboration between the Lundblad and Cech groups,
in which mutations of amino acids implicated in RT activ-
product is necessary for multiple rounds of addition.ity were shown to eliminate telomerase activity both in
Finally, the very N terminus of yeast TERT recruits an-vivo and in vitro (Lingner et al., 1997).
other telomerase subunit, Est3p, to the complex (Fried-As often happens in these days of the human genome
man et al., 2003), and additional protein-protein interac-project, the human version (hTERT) was found shortly
tions may remain to be discovered.thereafter (Meyerson et al., 1997; Nakamura et al., 1997).
It was expressed in a variety of transformed cells but
not detectable in primary cultures of human somatic Current Picture of Telomerase
We currently view telomerase as composed of an RNAcells, already giving a simple answer as to why telo-
merase activity was deficient in somatic cells. Thus, over molecule with a well-defined secondary structure, best
characterized in ciliates and vertebrates (Chen et al.,a short time span, we went from having no telomerase
protein to a whole family of TERTs (Telomerase Reverse 2000); the conserved TERT catalytic subunit; and a num-
ber of additional protein subunits, only some of whichTranscriptases).
TERT is now known to have several functions. The are conserved phylogenetically.
Three classes of proteins in addition to TERT are nowreverse transcriptase motifs, present in the C-terminal
half of the protein, provide the active site for catalysis. known to be associated with various telomerases. Est1p
was first found in yeast (Lundblad and Szostak, 1989);Several conserved amino acid sequence motifs in the
N-terminal half “rivet” the RNA component to the pro- it is essential for activity in vivo, but seems entirely
dispensable for enzyme activity per se as judged bytein, assuring maintenance of a stable RNP while
allowing the template to move through the active site in vitro assays. Est1p interacts directly with the yeast
telomere DNA end binding protein, Cdc13p (Pennock et(Bryan et al., 2000; Figure 2). Movement is essential,
as a single active site (the triangle in Figure 2) must al., 2001); this interaction appears to recruit telomerase
to the chromosome end (Pennock et al., 2001) andaccommodate addition of multiple nucleotides, after
which translocation of the template relative to the DNA somehow activate telomerase that is already associated
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with the telomere (Taggart et al., 2002). A human Est1
ortholog, EST1A, is associated with most or all active
telomerase in human cell extracts and is involved, either
directly or indirectly, in chromosome end-capping and
telomere elongation (Reichenbach et al., 2003; Snow
et al., 2003). Another yeast subunit, Est3p, is similarly
important for activity in vivo but not in vitro, with its
specific function unknown.
The two subunits of the Ku heterodimer comprise the
second class of telomerase proteins. Ku is responsible
for nonhomologous end-joining of broken chromo-
somes, and initially it appeared odd or perhaps even
dangerous that it would be telomere associated; after
all, telomeres protect chromosome ends from fusion
events that result in genomic instability. A solution to
this conundrum was recently provided by Stellwagen et
al. (2003), who showed that Ku binds directly to telo-
Figure 3. Telomerase RNA Functions
merase RNA and promotes the de novo addition of telo-
The S. cerevisiae telomerase RNA (1.2 kb) functions in part to bringmeres to broken chromosome ends, thereby helping
proteins into the complex. Curved lines represent regions where the
heal DNA damage by capping the broken end with telo- RNA secondary structure has not yet been reported.
meric DNA.
Finally, a large variety of proteins contribute to the
assembly and maturation of the telomerase RNP, and how the template portion is identified by TERT. After all,
these vary much more in evolution than TERT and the the RNA subunits contain hundreds or even a thousand
other proteins listed above. Budding yeast telomerase nucleotides, depending on the organism, and the tem-
RNA is an RNA polymerase II transcript, and its intracel- plate is not the only single-stranded region in the RNA
lular transport and assembly are mediated by the same that could in principle make a few base pairs with a DNA
Sm proteins found in the small nuclear RNPs involved primer and be reverse transcribed. This problem has
in RNA splicing (Seto et al., 1999). Current evidence been most successfully tackled in Tetrahymena, where a
suggests that the RNA may be made in the nucleus, short “template-recognition” sequence element directs
exported to the cytoplasm to pick up protein compo- the use of 5 adjacent nucleotides as the template for
nents, and then reimported into the nucleus where it DNA synthesis (Miller and Collins, 2002). Whether this
functions (Ferrezuelo et al., 2002; Teixeira et al., 2002). template-recognition element directly binds to TERT or
Human telomerase RNA, also a pol II transcript, has a interacts with another portion of the RNA remains a
snoRNP (small nucleolar RNP) domain, appears to be question for future research.
matured in the nucleolus, and binds dyskerin and other The yeast and human telomerases have been ob-
snoRNP proteins (Mitchell et al., 1999; Pogacic et al., served as dimers containing two functionally interacting
2000). Defects in the RNA or the dyskerin protein that RNA molecules (Ly et al., 2003 and references therein).
interrupt this maturation can lead to a human disease,
Thus, telomerase and retroviruses resemble each other,
dyskeratosis congenita (Mitchell et al., 1999; Vulliamy
not just in their reverse transcriptase proteins, but also
et al., 2001). Ciliate telomerase RNA is transcribed in-
in their “packaging” of their RNA template as a dimer.stead by pol III and, at least in Euplotes, is bound by a
Because recombinant Tetrahymena telomerase is activetelomerase-specific La-motif protein p43 that may shep-
as a monomer (one RNA  one TERT), dimerization isherd its maturation or confer nuclear localization (Aigner
not always required for core enzymatic activity (Bryanet al., 2003).
et al., 2003).Returning to the RNA component, it is now seen to
provide much more than the template. One class of
Regulation of Telomeraseadditional functions is to provide specific binding sites
In the most general sense, telomere length either isfor many of the proteins listed above. All telomerases
maintained at a steady-state distribution or undergoesexist as stable RNPs, and the RNA sequences responsi-
progressive shortening or lengthening depending on atble for TERT binding have been identified in several
least two considerations: the level of the telomeraseorganisms (Mitchell and Collins, 2000; Chen et al., 2002;
RNP and the state of the telomere itself.Livengood et al., 2002). In yeast, the Ku protein binds
Human telomerase is regulated during developmentto one RNA secondary structure element (Stellwagen et
by the first of these factors—telomerase expression isal., 2003) and Est1p to a separate bulged stem (Seto et
dramatically reduced in many somatic cells during em-al., 2002) (Figure 3). RNA binding sites for the yeast Sm
bryonic development, and therefore chromosome endsproteins and the human snoRNP proteins have similarly
shrink with successive cell divisions (Wright et al., 1996).been defined. In the second class of functions, the RNA
In these cells, the limiting component is hTERT, and themay be acting directly to promote a specific feature
transcriptional repression of the hTERT gene leads to aof catalysis. Clear examples are the base-paired RNA
loss of telomerase activity. An unidentified repressorelements that form template boundaries to terminate
encoded on chromosome 3 controls the state of hTERTeach cycle of reverse transcription in yeast and human
chromatin, leading to transcriptional silencing (Szutorisztelomerase (Tzfati et al., 2000; Chen and Greider, 2003).
One key question about telomerase RNA concerns et al., 2003). Specifically, three tumor suppressor path-
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ways have been identified as negative regulators of
hTERT transcription: Mad1, a repressor of c-Myc; TGF-
, acting through SIP1; and Menin, binding directly to
the hTERT promoter (Lin and Elledge, 2003). Human
cells that retain readily detectable telomerase activity
include some proliferating epithelial cells, lymphocytes,
and testis. Stem cells have weak telomerase activity
(reviewed by Collins and Mitchell, 2002). Even in somatic
cells where the level of telomerase activity is undetect-
able by standard assays, one needs to be aware of
the limit of detection. Recently, immunopurification has
been used to reveal that there is in fact some expression
of hTERT and telomerase activity in cycling human fibro-
blasts, and that this low level of activity has biological
consequences (Masutomi et al., 2003).
Some cells that lack telomerase activity, on the other
hand, still have a high level of hTERT transcription. In
these cases, regulation at the level of alternative splicing
leads to skipping of exons that encode reverse tran-
scriptase function, so any translation product would not
give an active enzyme (Ulaner et al., 1998).
In addition to the developmental regulation mentioned
above, telomere length regulation in all organisms from
yeast to human involves the accessibility of the telomere
to telomerase. This appears to occur at four different
levels, as follows:
(1) Double-stranded telomeric DNA binding proteins
such as Rap1p in budding yeast are involved in telomere
length regulation (e.g., Marcand et al., 1997; Ray and
Runge, 1999). Data support the “protein counting
model,” in which Rap1p binds Rif1p and Rif2p to nucle-
ate the formation of a folded chromatin structure at the
telomere, thereby preventing access by telomerase. As Figure 4. Pot1 (Protection of Telomeres) Protein from S. pombe
the telomere shortens due to incomplete replication, Binds Single-Stranded Telomeric DNA (GGTTAC)
the number of protein binding sites decreases and the Two views of the X-ray crystal structure of the complex are shown
chromatin opens up to restore access to telomerase. (Lei et al., 2003). The six bases are bound as three stacked pairs;
arrows indicate the 5-most pair (GG).The human telomeric dsDNA binding proteins, TRF1 and
TRF2 (Smogorzewska et al., 2000), may act by a similar
mechanism. TRF1 recruits TIN2 (Kim et al., 1999) and
structure shows the ssDNA compacted and seques-TRF2 recruits hRAP1 (Li et al., 2000) through protein-
tered within the protein (Figure 4; Lei et al., 2003), consis-protein interactions. Similarly, in fission yeast, the
tent with human POT1 acting as a repressor of telo-dsDNA binding protein Taz1 recruits Rap1 and Rif1 (Ka-
noh and Ishikawa, 2001). Surprisingly, some aspects of merase (Loayza and de Lange, 2003). Under other
telomere chromatin structure and function, including the conditions, human POT1 can stimulate telomere elonga-
binding of Taz1, are maintained in circular chromosomes tion (Colgin et al., 2003), perhaps in analogy to yeast
that have no telomeric repeats (Sadaie et al., 2003). Cdc13p. Telomeric single-stranded DNA binding pro-
(2) Long telomeres, including those in human cells, teins may also control the action of nucleases that gen-
can form a “t loop” structure in which the entire telomeric erate the G strand overhangs at chromosome ends (Ja-
DNA forms a large circle; the 3 single-stranded DNA cob et al., 2003).
tail invades the double-stranded telomeric DNA to form (4) Single-stranded telomeric DNA tails also become
a D loop (Griffith et al., 1999). The t loop presumably resistant to telomerase extension when they fold into
provides chromosome end protection and also renders quadruplex structures, a proclivity of guanine-rich se-
the DNA terminus inaccessible to telomerase. Double- quences. The extent to which this occurs in vivo is
stranded DNA binding proteins such as TRF1 and 2 unknown. However, small molecules that bind to quad-
might exert their effects on telomere length regulation ruplex structures can push the equilibrium toward this
in part by modulating t loop formation. folded form, providing a credible approach to telo-
(3) Proteins that bind the 3 single-stranded DNA tail merase inhibition (Kim et al., 2002).
are involved in regulation of telomerase since the 3 end
cannot simultaneously bind the protein and the align-
Cellular Immortalityment region of the telomerase RNA. The role of yeast
Telomeres shorten during serial passage of human fibro-Cdc13p in recruiting telomerase was described above.
blasts in vitro (Harley et al., 1990). Early proposals thatThe Protection of Telomeres (POT1) protein appears to
telomere length determines the number of cell divisionsbe the analog of Cdc13 in fission yeast, plants, mice,
and humans (Baumann and Cech, 2001). A recent X-ray a cell can undergo—the Hayflick Limit—were based on
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such correlation between telomere length and prolifera- merase. The drug induces senescence rather than apo-
ptosis in human cancer cells, and the inhibition of bothtive potential. The availability of hTERT allowed a direct
test of this proposal. When hTERT was transfected into cell growth and telomerase are fully reversible upon
removal of the drug (Damm et al., 2001). Although thefibroblasts or retinal epithelial cells, they had a greatly
extended lifespan, apparently limitless, while control difference in results could be due to the different cell
lines used, it is also possible that the way in whichcells transfected with empty vector underwent senes-
cence at the Hayflick Limit as expected (Bodnar et al., telomerase is inhibited is the decisive factor. DN-TERT
may inhibit by titrating telomerase or telomere compo-1998). This apparent immortalization differed from onco-
genic transformation in that the hTERT-transfected cells nents from the chromosome end, thereby perturbing
capping, while the small molecule inhibitor may simplydid not develop chromosome abnormalities, were un-
able to grow on soft agar, and were not tumorigenic. T decrease the catalytic activity of the telomerase enzyme
without perturbing the amount or location of telomeraselymphocytes also achieved dramatic extension of their
replicative lifespan upon ectopic expression of hTERT or its protein-protein contacts. For this reason, it will be
interesting to test whether small molecule inhibitors of(Hooijberg et al., 2000; Rufer et al., 2001). Mammary
epithelial cells and keratinocytes, on the other hand, catalytic activity are less toxic for normal cells than
DN-TERT or RNAi, which may be more likely to perturbrequired inactivation of the Rb/p16 tumor suppressor
pathway in addition to activation of hTERT in order to chromosome capping.
achieve extended lifespan (Kiyono et al., 1998).
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